Results 41 to 50 of about 6,194,408 (253)

Myanmar: The impact of COVID-19 and food system responses

, 2021
In Myanmar, the COVID-19 pandemic and political upheaval have both had significant economic and social repercussions. CGIAR has been working with partners in the country to assess the economic impacts of the pandemic and their consequences for agrifood ...
COVID-19 Hub
core   +1 more source

Bangladesh: The impact of COVID-19 and food system responses

, 2021
While Bangladesh has had reactionary responses to the newer waves of COVID-19, it is projected that the country could face severe consequences if the Delta variant detected in May 2021 spreads. Since the beginning of the health crisis, CGIAR and partners
COVID-19 Hub
core   +1 more source

Critical appraisal in rapid systematic reviews of COVID-19 studies: implementation of the Quality Criteria Checklist (QCC)

Systematic Reviews, 2023
In this letter, we briefly describe how we selected and implemented the quality criteria checklist (QCC) as a critical appraisal tool in rapid systematic reviews conducted to inform public health advice, guidance and policy during the COVID-19 pandemic ...
Daphne Duval, Nicola Pearce-Smith, Jennifer C. Palmer, Jason Kwasi Sarfo-Annin, Paul Rudd, Rachel Clark   +5 more
doaj   +1 more source

Ethiopia: The impact of COVID-19 and food system responses

, 2021
In Ethiopia, the COVID-19 pandemic has affected livelihoods and caused declines in the gross domestic product (GDP) of the agrifood system (AFS) as well as in total GDP.
COVID-19 Hub
core   +1 more source

The COVID-19 Vaccine Safety Research Center: a cornerstone for strengthening safety evidence for COVID-19 vaccination in the Republic of Korea [PDF]

Osong Public Health and Research Perspectives
The COVID-19 Vaccine Safety Research Committee (CoVaSC) was established in November 2021 to address the growing need for independent, in-depth scientific evidence on adverse events (AEs) following coronavirus disease 2019 (COVID-19) vaccination.
Na-Young Jeong, Hyesook Park, Sanghoon Oh, Seung Eun Jung, Dong-Hyun Kim, Hyoung-Shik Shin, Hee Chul Han, Jong-Koo Lee, Jun Hee Woo, Jaehun Jung, Joongyub Lee, Ju-Young Shin, Sun-Young Jung, Byung-Joo Park, Nam-Kyong Choi   +14 more
doaj   +1 more source

Evaluation of self-administered antigen testing in a college setting

Virology Journal, 2022
Background The objective of our investigation was to better understand barriers to implementation of self-administered antigen screening testing for SARS-CoV-2 at institutions of higher education (IHE).
Sarah C. Tinker, Jessica L. Prince-Guerra, Kelly Vermandere, Jenna Gettings, Cherie Drenzik, Gary Voccio, Tonia Parrott, Jan Drobeniuc, Tonya Hayden, Stephen Briggs, Debbie Heida, Natalie Thornburg, Lisa C. Barrios, John C. Neatherlin, Sabrina Madni, Catherine N. Rasberry, Kenneth D. Swanson, Azaibi Tamin, Jennifer L. Harcourt, Sandra Lester, Lydia Atherton, Margaret A. Honein   +21 more
doaj   +1 more source

Malawi: The impact of COVID-19 and food system responses

, 2021
Malawi, like other southern African countries, has endured several waves of infection since the COVID-19 pandemic started. The disease has had severe effects on the economy, including the agriculture sector.
COVID-19 Hub
core   +1 more source

Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future

Inflammation and Regeneration, 2020
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in Wuhan, China, and has spread globally to most countries. In Japan, the first COVID-19 patient was identified on January 15, 2020.
Tokio Hoshina, Hiroka Aonuma, Manabu Ote, Tatsuya Sakurai, Erisha Saiki, Yuki Kinjo, Kazuhiro Kondo, Masataka Okabe, Hirotaka Kanuka   +8 more
doaj   +1 more source

A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

, 2021
BACKGROUND: Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody) may attenuate the inflammatory response in Covid-19. METHODS: We performed an adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial of intravenous sarilumab 200 ...
DiCioccio, A. Thomas, Saggar, Suraj, Sivapalasingam, Sumathi, Aberg, Judith A., Kampman, Wendy, Ferreira, Manuel A., Kosmicki, Jack A., Parrino, Jani, Boyapati, Anita, Criner, Gerard, Hosain, Romana, Labriola-Tompkins, Emily, Akinlade, Bolanle, Brown, Samuel M., Weinreich, David M., Bhore, Rafia, Ng Gong, Michelle, Horowitz, Julie E., Hajizadeh, Negin, Sobieszczyk, Magdalena E., Park, William, Gulabani, Daya, Yancopoulos, George D., Mahmood, Adnan, Lederer, David J., Sperber, Steven J., Musser, Bret, Stein, David K., Baras, Aris, Giannelou, Angeliki, Menon, Vidya, Somersan-Karakaya, Selin, O’Brien, Meagan, Purcell, Lisa A., Nivens, Michael C., Herman, Gary, Kowal, Bari, Waldron, Alpana, Braunstein, Ned, Ramesh, Divya   +39 more
core   +1 more source

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

, 2022
BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized,
Boulware, David R., Stewart, Thomas G., Adam, Stacey J., Castro, Mario, Lindsell, Christopher J., Hanna, George, Ruiz-Unger, Juan, Singh, Upinder, Gentile|, Hernandez, Adrian F., Wilder, Rhonda, Thicklin, Florence, McTigue, Kathleen, Ginde, Adit A., Bramante, Carolyn, DeLong, Allison, Felker, G. Michael, Dolor, Rowena J., McCarthy, Matthew W., Wilson, Sybil, Sulkowski, Mark, Collins, Sean, Dunsmore, Sarah E., Jayaweera, Dushyantha, Remaly, April, Gentile, Nina, Naggie, Susanna, Shenkman, Elizabeth   +27 more
core   +1 more source